Go Pro
→ Louis Navellier: My #1 AI stock for 2026 (name & ticker inside) (From InvestorPlace) (Ad)tc pixel
NASDAQ:CELU

Celularity Q1 2026 Earnings Report

Celularity logo
$1.35 -0.02 (-1.46%)
Closing price 09/30/2026 04:00 PM Eastern
Extended Trading
$1.34 -0.01 (-0.37%)
As of 04:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Celularity EPS Results

Actual EPS
$0.02
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Celularity Revenue Results

Actual Revenue
$3.85 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Celularity Announcement Details

Quarter
Q1 2026
Date
9/29/2026
Time
After Market Closes
Conference Call Date
Tuesday, September 29, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

Celularity's Q2 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

Celularity's Q1 2026 Quarterly reportQuarterly report
(10-Q)

Celularity Earnings Headlines

Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner
September 30 at 11:57 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/30/3372229/0/en/celularity-highlights-anticipated-quarter-one-2027-opening-of-fontaine-vitale-as-strategic-partner.html
Celularity (NASDAQ:CELU) Releases Quarterly Earnings Results
September 30 at 7:26 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31069017
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
 |  InvestorPlace (Ad)
Celularity Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
September 29 at 10:19 PM  |  marketscreener.comM
Celularity Inc. ernennt Naveen Jain zum Verwaltungsratsmitglied
September 29 at 10:19 PM  |  de.marketscreener.comD
Celularity Inc. Announces Appointment of Naveen Jain as Director
September 29 at 5:18 PM  |  marketscreener.comM
See More Celularity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email.

About Celularity

Celularity (NASDAQ:CELU) is a biotechnology company developing allogeneic cell therapies and biomaterial products derived from human placenta. The company’s research focuses on using placental cells and tissues to address unmet needs in oncology, immune-mediated diseases and regenerative medicine.

Celularity’s therapeutic pipeline has included CYNK-001, an off-the-shelf natural killer cell therapy being investigated for certain blood cancers, as well as other engineered and unmodified placental-derived cell programs. The company has also developed placental-derived biomaterial products intended to support wound care and tissue repair.

Founded in 2016, Celularity is headquartered in Florham Park, New Jersey. The company was founded by Robert J. Hariri, M.D., Ph.D., who has served in senior leadership roles, including chief executive officer and chairman. Its products and clinical programs are intended for use in the United States and other markets where regulatory authorization or clinical development is available.

View Celularity Profile
Earnings Tools